RDC Clinical Pty Ltd
New Farm, Queensland, 4006, Australia
NCT Number: NCT05950841
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed IHAT (iron hydroxide adipate tartrate) at 2 different doses compared to placebo for increasing serum ferritin levels in iron-deficient but otherwise healthy premenopausal women over 12 weeks.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 3
New Farm, Queensland, 4006, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Footnotes
Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)
Twice daily dose of 1 capsule (100mg per capsule IHAT)
Twice daily dose of 1 capsule (carob flour)
Time frame: Week 12
Percentage of women recovering from ID at week 12, defined as serum ferritin levels of 30 -150 ug/L
Time frame: Baseline, week 6 and week 12
Time to reach normalisation of ferritin levels via blood test results
Time frame: Baseline, week 6 and week 12
Iron Status (Serum ferritin, Hb levels, Serum iron levels, TSAT levels, NTBI) via blood test
Time frame: Baseline, weeks 1 - 5, week 6 and week 12
Time frame: Baseline, week 6 and week 12
Change in fatigue via Fatigue Severity Questionnaire
Time frame: Baseline, week 6 and week 12
Iron deficiency symptoms via SF-36 Questionnaire
RDC Clinical Pty Ltd
Industry
A Randomised, Double-blind Study to Determine the Safety and Efficacy of IHAT in Iron Deficient Premenopausal Women.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04945707
Anemia, Anemia, Hypochromic
Boston, Massachusetts, United States
View Trial DetailsNCT04206228
Anemia, Anemia, Hypochromic
Oslo, Norway
View Trial DetailsNCT04810546
Anemia, Anemia, Hypochromic
Chicago, Illinois, United States
View Trial DetailsNCT05309499
Anemia, Anemia, Hypochromic
Kazan', Tatarstan Republic, Russia
View Trial Details